NEW YORK (GenomeWeb News) – Gentronix today said that it will provide GlaxoSmithKline with its genotoxicity detection assay, GreenScreen HC, for use in the drug firm's safety evaluation studies.

According to Manchester, UK-based Gentronix, GreenScreen HC is the first human cell-based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay uses green fluorescent protein to detect GADD-45a up regulation, which is a key indicator of DNA damage, said Gentronix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.